PFE-US Reports Q2 Earnings and Revenue Surpass Expectations, Upgrades Full-Year EPS Guidance
A financial news app has learned that Pfizer (PFE.US) announced its second-quarter earnings on Tuesday, benefiting from strong demand for heart disease medication Vyndaqel and blood thinner Eliquis. The company's revenue and profit both exceeded analysts' expectations, and it also upgraded its full-year EPS guidance. The company's stock price rose by over 3% in pre-market trading before closing up 1.7%.
The data shows that Pfizer's second-quarter earnings per share (EPS) was $0.78, far exceeding the market consensus estimate of $0.57; and its revenue grew 10% to $147 billion, also surpassing the expected $134.7 billion.
Pfizer Chairman and CEO Albert Bourla, MD, stated: "Pfizer has had another strong quarter focused on executing our strategy, and we are pleased with our progress in advancing our pipeline, enhancing commercial performance, and expanding our profit margins."
Pfizer currently estimates that its adjusted EPS for 2025 will be $2.90 to $3.10, which was previously estimated at $2.80 to $3.00. The midpoint of the upgraded guidance is $0.10 higher than the market consensus estimate of $3.01. Full-year revenue guidance remains unchanged at $610 billion to $640 billion.
Pfizer noted that its revised EPS guidance reflects the strong performance in the first half, cost savings, reduced tax rates, and favorable currency exchange rate movements. The guidance also takes into account a one-time $13.5 billion research expense related to Pfizer's authorization agreement with 3SBio, which is expected to reduce third-quarter EPS by approximately $0.20.
Pfizer released its earnings at a time when the pharmaceutical industry is facing multiple challenges: the Trump administration's continued push for drug price reductions and the planned tariffs of up to 15% on European Union imports. In response, Pfizer stated that it has sufficient production capacity at its 10 US-based manufacturing facilities, which can help mitigate the impact of tariffs and is willing to transfer some production to these existing facilities.
Investors are closely watching whether Health and Human Services Secretary Robert Kennedy (RFK Jr.), a well-known vaccine skeptic, may use policy changes to affect Pfizer's vaccine product line. Vaccines account for approximately 20% of Pfizer's total revenue.
The company said that its guidance has fully taken into account the current tariff impact as well as any potential policy actions related to drug pricing that may be announced after Trump's letter in late July.